All Stories

  1. Functionalization at C-2 of L-idose and L-iduronic acid derivatives
  2. Light-Promoted Synthesis of Glycosyl Bromides in Flow
  3. Systematic Virtual Screening of Heparan Sulfate Oligosaccharides and Mechanistic Insights into Heparanase Inhibition
  4. Correction to “Synthesis of a C‐2 Functionalized L‐Iduronic Acid Derivative as a Candidate Pharmacological Chaperone for MPS II (Hunter Syndrome)”
  5. Light-Promoted Synthesis of Glycosyl Bromides in Flow
  6. Synthesis of a C‐2 Functionalized l ‐Iduronic Acid Derivative as a Candidate Pharmacological Chaperone for MPS II (Hunter Syndrome)
  7. Fully Synthetic Non‐Carbohydrate Heparin Mimetics—Perspectives for Therapeutic Anticoagulation and Beyond?
  8. Comparing Heparin and Heparin Mimetics in Targeting Immunomodulatory Proteins from Platelets to Activate T Cell-Dependent Immune Response in Oncology
  9. Heparin and synthetic heparin mimetics – Do they act as potential immunomodulators in an in vitro metastatic context?
  10. Heparan-N-sulfatase and N-acetyl-α-glucosaminidase: Mechanisms, mutations, biophysical studies, and chaperone development
  11. Functionalization at C-2 of L-Idose and L-Iduronic Acid Derivatives
  12. Purple Light-Promoted Ferrier Photobromination of O -Benzoylated Carbohydrates in Benzotrifluoride
  13. Purple Light-Promoted Ferrier Photobromination of O-Benzoylated Carbohydrates in Benzotrifluoride
  14. Substrate reduction using a glucosamine analogue in Drosophila melanogaster and mouse models of Sanfilippo syndrome
  15. Efficient Synthesis of Fluorogenic Substrates for Mucopolysaccharidosis (MPS) IIIA and IIIB Via Aromatic α-Glycosylation with Thioglycosyl Donors
  16. A Novel Series of Synthetic Heparin‐Mimetics–Itaconic Acid‐Containing Copolymers for Targeting Tumor Cell Coagulability and Metastasis
  17. Synthetic glycol-split heparin tri- and tetrasaccharides provide new insights into structural peculiarities for antiheparanase activity
  18. Efficient synthesis of fluorogenic substrates for mucopolysaccharidosis (MPS) IIIA and IIIB via aromatic α-glycosylation with thioglycosyl donors
  19. Gold( i ) and gold( iii ) complexes of triazolyl-functionalised NHCs
  20. A Heparan Sulfate Mimetic RAFT Copolymer Inhibits SARS‐CoV‐2 Infection and Ameliorates Viral‐Induced Inflammation
  21. Synthetic Access to l-Guluronic Acid via Fluorine-Directed C-5 Epimerization
  22. Synthesis of a deuterated disaccharide internal standard for LC-MS/MS quantitation of heparan sulfate in biological samples
  23. Sulfated Alginate for Biomedical Applications
  24. Amphiphilic Heparinoids as Potent Antiviral Agents against SARS-CoV-2
  25. Site-Selective Photobromination of O-Acetylated Carbohydrates in Benzotrifluoride
  26. Origins of Temperature‐Dependent Anomeric Selectivity in Glycosylations with an L‐Idose Thioglycoside
  27. Site-Selective Photobromination of O-Acetylated Carbohydrates in Benzotrifluoride
  28. Synthetic Access to L-Guluronic Acid via Fluorine-Directed C-5 Epimerization
  29. Antiviral Activities of Heparan Sulfate Mimetic RAFT Polymers Against Mosquito-borne Viruses
  30. Synthesis of sulfated alginate from its tributylammonium salt: Comparing the sulfating agents H2SO4-DCC and SO3·py
  31. Synthesis of a Deuterated Disaccharide Internal Standard for Lc-Ms/Ms Quantitation of Heparan Sulfate  in Biological Samples
  32. Synthetic Glycol-Split Heparin Tri- and Tetrasaccharides Provide New Insights into Structural Peculiarities for Antiheparanase Activity
  33. Identification of a Pentasaccharide Lead Compound with High Affinity to the SARS-CoV-2 Spike Protein via In Silico Screening
  34. C-5 Epimerisation of D-Mannopyranosyl Fluorides: The Influence of Anomeric Configuration on Radical Reactivity
  35. Substrate reduction therapy in aDrosophila melanogastermodel of Sanfilippo syndrome
  36. A prohibitin-targeting drug modifies aspects of disease in a mouse model of Sanfilippo syndrome
  37. Synthesis of Uronic Acid 1‐Azasugars as Putative Inhibitors of α‐Iduronidase, β‐Glucuronidase and Heparanase**
  38. Siderophore conjugates to combat antibiotic-resistant bacteria
  39. An Enzymatic Activity Assay for Heparanase That Is Useful for Evaluating Clinically Relevant Inhibitors and Studying Kinetics
  40. Synthesis of a Gal-β-(1→4)-Gal disaccharide as a ligand for the fimbrial adhesin UcaD
  41. Evidence for Multiple Binding Modes in the Initial Contact Between SARS‐CoV‐2 Spike S1 Protein and Cell Surface Glycans**
  42. Synthesis of Uronic Acid 1-Azasugars as Putative Inhibitors of a-Iduronidase, b-Glucuronidase and Heparanase
  43. An Improved Protocol for the Stereoselective Synthesis of β-d-Glycosyl Fluorides from 2-O-Acyl Thioglycosides
  44. Initial contact between SARS-CoV-2 spike S1 protein and cell surface glycans involves multiple binding modes
  45. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction
  46. Au‐NHC complexes with thiocarboxylate ligands: Synthesis, structure, stability, thiol exchange and in vitro anticancer activity
  47. Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin
  48. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections
  49. SARS-CoV-2 Triggers Complement Activation through Interactions with Heparan Sulfate
  50. SARS‐CoV‐2 triggers complement activation through interactions with heparan sulfate
  51. Development of Improved Synthetic Routes to Pixatimod (PG545), a Sulfated Oligosaccharide-Steroid Conjugate
  52. From Cancer to COVID‐19: A Perspective on Targeting Heparan Sulfate‐Protein Interactions
  53. Corrigendum: Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo
  54. A Substituent‐Directed Strategy for the Selective Synthesis of L‐Hexoses: An Expeditious Route to L‐Idose
  55. Inhibition of Tumor–Host Cell Interactions Using Synthetic Heparin Mimetics
  56. Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain
  57. Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin
  58. GlycoTorch Vina: Docking Designed and Tested for Glycosaminoglycans
  59. Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo
  60. Sulfonated RAFT Copolymers as Heparin Mimetics: Synthesis, Reactivity Ratios, and Anticoagulant Activity
  61. A Fluorogenic Heparan Sulfate Disaccharide for the Measurement of Heparanase Activity
  62. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 By Disrupting The Spike-ACE2 interaction
  63. Heparanase promotes Syndecan-1 expression to mediate fibrillar collagen and mammographic density in human breast tissue cultured ex vivo
  64. GlycoTorch Vina: Improved Docking of Sulfated Sugars Using QM-derived Scoring Functions
  65. PI-88 and Related Heparan Sulfate Mimetics
  66. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment
  67. Structural insights into heparanase activity using a fluorogenic heparan sulfate disaccharide
  68. Anticoagulant Heparin Mimetics via RAFT Polymerization
  69. Synthetic Disaccharide Standards Enable Quantitative Analysis of Stored Heparan Sulfate in MPS IIIA Murine Brain Regions
  70. PG545 treatment reduces RRV-induced elevations of AST, ALT with secondary lymphoid organ alterations in C57BL/6 mice
  71. Dual targeting of dengue virus virions and NS1 protein with the heparan sulfate mimic PG545
  72. In Vitro Enzymatic Digestibility of Glutaraldehyde-Crosslinked Chitosan Nanoparticles in Lysozyme Solution and Their Applicability in Pulmonary Drug Delivery
  73. Cross-Species Analysis of Glycosaminoglycan Binding Proteins Reveals Some Animal Models Are “More Equal” than Others
  74. The Development of Assays for Heparanase Enzymatic Activity: Towards a Gold Standard
  75. Applications of Ion Mobility-Mass Spectrometry in Carbohydrate Chemistry and Glycobiology
  76. Structural and conformational studies of the heparan sulfate mimetic PI-88
  77. Glycosylations of Simple Acceptors with 2-O -Acyl l -Idose or l -Iduronic Acid Donors Reveal Only a Minor Role for Neighbouring-Group Participation
  78. Heparin mimetics with anticoagulant activity
  79. Prophylactic Antiheparanase Activity by PG545 Is Antiviral In Vitro and Protects against Ross River Virus Disease in Mice
  80. Synthesis and mass spectrometric analysis of disaccharides from methanolysis of heparan sulfate
  81. New structural insights into the oligosaccharide phosphate fraction of Pichia ( Hansenula ) holstii NRRL Y2448 phosphomannan
  82. Carbohydrate– N -heterocyclic carbene metal complexes: Synthesis, catalysis and biological studies
  83. Glycosaminoglycans and Their Mimetics
  84. Effects of Chemical Conjugation of l-Leucine to Chitosan on Dispersibility and Controlled Release of Drug from a Nanoparticulate Dry Powder Inhaler Formulation
  85. Recent advances in chitosan-based nanoparticulate pulmonary drug delivery
  86. Synthesis of Mannose-Cholesterol Conjugates for Targeted Liposomal Drug Delivery
  87. The Tortoise and the Hare: Evolving Regulatory Landscapes for Biosimilars
  88. The stereoselectivities of tributyltin hydride-mediated reductions of 5-bromo-d-glucuronides tol-iduronides are dependent on the anomeric substituent: syntheses and DFT calculations
  89. Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk
  90. Investigations into the decomposition of aminoacyl-substituted monosaccharide scaffolds from a drug discovery library
  91. Synthetic Approaches to l-Iduronic Acid and l-Idose
  92. Synthesis and Toxicological Evaluation of a Chitosan- l -Leucine Conjugate for Pulmonary Drug Delivery Applications
  93. ChemInform Abstract: Attempted Synthesis of the Imidazylate (III) of an α-Hydroxylactone (I) Results in Unexpected Chlorination: Synthesis and X-Ray Crystal Structure of 5-Chloro-5-deoxy-1,2-O-isopropylidene-β-L-idurono-6,3-lactone (II).
  94. Attempted Synthesis of the Imidazylate of an α-Hydroxylactone Results in Unexpected Chlorination: Synthesis and X-Ray Crystal Structure of 5-Chloro-5-deoxy-1,2-O-isopropylidene-β-l-idurono-6,3-lactone
  95. Low-molecular-weight heparin biosimilars: potential implications for clinical practice
  96. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase
  97. Structure and stereochemistry of an anti-inflammatory anhydrosugar from the Australian marine sponge Plakinastrella clathrata and the synthesis of two analogues
  98. Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses
  99. ChemInform Abstract: A Focused Sulfated Glycoconjugate Ugi Library for Probing Heparan Sulfate-Binding Angiogenic Growth Factors.
  100. MicroRNAs Regulate Tumor Angiogenesis Modulated by Endothelial Progenitor Cells
  101. A focused sulfated glycoconjugate Ugi library for probing heparan sulfate-binding angiogenic growth factors
  102. Synthesis of Disaccharides Containing 6-Deoxy-a-L-talose as Potential Heparan Sulfate Mimetics
  103. Synthesis of a Heparan Sulfate Mimetic Library Targeting FGF and VEGF via Click Chemistry on a Monosaccharide Template
  104. Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis
  105. Potent anti-respiratory syncytial virus activity of a cholestanol-sulfated tetrasaccharide conjugate
  106. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
  107. Synthesis of simple heparanase substrates
  108. Lipophile-conjugated sulfated oligosaccharides as novel microbicides against HIV-1
  109. A highly lipophilic sulfated tetrasaccharide glycoside related to muparfostat (PI-88) exhibits virucidal activity against herpes simplex virus
  110. Synthesis and Biological Evaluation of Polysulfated Oligosaccharide Glycosides as Inhibitors of Angiogenesis and Tumor Growth
  111. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening
  112. Synthesis of a heparan sulfate mimetic disaccharide with a conformationally locked residue from a common intermediate
  113. ChemInform Abstract: An Improved Synthetic Route to the Potent Angiogenesis Inhibitor Benzyl Manα(1→3)Manα(1→3)-Manα (1→3)Manα(1→2)-Man Hexadecasulfate.
  114. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
  115. An Improved Synthetic Route to the Potent Angiogenesis Inhibitor Benzyl Manα(1→3)-Manα(1→3)-Manα(1→3)-Manα(1→2)-Man Hexadecasulfate
  116. A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins
  117. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88
  118. Design, synthesis, FGF-1 binding, and molecular modeling studies of conformationally flexible heparin mimetic disaccharides
  119. Molecular basis for resistance of herpes simplex virus type 1 mutants to the sulfated oligosaccharide inhibitor PI-88
  120. Herpes Simplex Virus Type 2 Glycoprotein G Is Targeted by the Sulfated Oligo- and Polysaccharide Inhibitors of Virus Attachment to Cells
  121. PI-88 and Novel Heparan Sulfate Mimetics Inhibit Angiogenesis
  122. Enantiospecific synthesis of the heparanase inhibitor (+)-trachyspic acid and stereoisomers from a common precursor
  123. Inhibition of Plasmodium falciparum Growth In Vitro and Adhesion to Chondroitin-4-Sulfate by the Heparan Sulfate Mimetic PI-88 and Other Sulfated Oligosaccharides
  124. Synthesis, Biological Activity, and Preliminary Pharmacokinetic Evaluation of Analogues of a Phosphosulfomannan Angiogenesis Inhibitor (PI-88)
  125. Towards the synthesis of aryl glucuronides as potential heparanase probes. An interesting outcome in the glycosidation of glucuronic acid with 4-hydroxycinnamic acid
  126. The Synthesis and Biological Evaluation of Two Analogues of the C-Riboside Showdomycin.
  127. Use of Sulfated Linked Cyclitols as Heparan Sulfate Mimetics to Probe the Heparin/Heparan Sulfate Binding Specificity of Proteins
  128. The Synthesis and Biological Evaluation of Two Analogues of the C -Riboside Showdomycin
  129. The synthesis of phosphorylated disaccharide components of the extracellular phosphomannan of Pichia (Hansenula) holstii NRRL Y-2448
  130. A Synthetic Heparanase Inhibitor Reduces Proteinuria in Passive Heymann Nephritis
  131. Application of the Four-Component Ugi Condensation for the Preparation of Sulfated Glycoconjugate Libraries.
  132. The Development of Inhibitors of Heparanase, a Key Enzyme Involved in Tumour Metastasis, Angiogenesis and Inflammation
  133. The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus
  134. Application of the four-component Ugi condensation for the preparation of sulfated glycoconjugate libraries
  135. Probing the Interactions of Phosphosulfomannans with Angiogenic Growth Factors by Surface Plasmon Resonance
  136. Preparation and anticoagulant activity of the phosphosulfomannan PI-88
  137. PROBING THE INTERACTIONS OF PI-88 WITH ANGIOGENIC GROWTH FACTORS BY SURFACE PLASMON RESONANCE
  138. SULFATED OLIGOSACCHARIDE-BASED INHIBITORS OF TUMOUR GROWTH AND METASTASIS
  139. INHIBITION OF HERPES SIMPLEX VIRUS INFECTION BY PI-88, AN ANTAGONIST OF HEPARAN SULFATE-PROTEIN INTERACTIONS
  140. HEPARAN SULFATE-MIMETICS AS INHIBITORS OF CANCER
  141. Determination of the composition of the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y-2448 phosphomannan by capillary electrophoresis and HPLC
  142. Synthesis of [14C]- and [35S]-labelled PI-88 for pharmacokinetic and tissue distribution studies
  143. Characterisation of the Anticoagulant Properties of a Range of Structurally Diverse Sulfated Oligosaccharides
  144. Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88
  145. Article
  146. Convergent synthesis of a fluorescence-quenched glycopeptide as a potential substrate for peptide: N-glycosidases
  147. N-Glycosyl phosphonamidates: potential transition-state analogue inhibitors of glycopeptidases
  148. Internally quenched fluorogenic, α-helical dimeric peptides and glycopeptides for the evaluation of the effect of glycosylation on the conformation of peptides
  149. The Synthesis of Some Epoxyalkyl b-C-Glycosides as Potential Inhibitors of b-Glucan Hydrolases
  150. Analysis of the1H NMR spectra of some diethyl phosphonates
  151. Synthesis of 2′- and 2″-O-acylated maltotriosides as potential fluorescence-quenched substrates for α-amylase
  152. Approaches to the Synthesis of Retronecine From Some Pyrrolidine Precursors
  153. The Synthesis of Some Pyrrolidines as Potential Precursors to Retronecine
  154. An Improvement in the Preparation of Some Carbohydrate Benzylidene Acetals